Spark, Pfizer amend agreement for experimental hemophilia gene therapy – Philadelphia Business Journal
Philadelphia Business Journal |
Spark, Pfizer amend agreement for experimental hemophilia gene therapy
Philadelphia Business Journal Under the amended agreement, Spark Therapeutics, a Philadelphia gene therapy company spun out of Children's Hospital of Philadelphia, will enroll up to five additional participants in the current phase-I/II clinical trial testing the treatment known as … Spark Therapeutics (ONCE), Pfizer (PFE) Amend Pact for Investigational SPK-9001 in Hemophilia B |
